Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
7 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
8 Apr 24
8-K
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
8 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
7 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
S-8
Registration of securities for employees
20 Nov 23
8-K
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
9 Nov 23
8-K/A
Departure of Directors or Certain Officers
6 Nov 23
8-K/A
Departure of Directors or Certain Officers
2 Nov 23
8-K
Termination of a Material Definitive Agreement
31 Oct 23
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
16 Oct 23
8-K
Results of Operations and Financial Condition
31 Jul 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
8-K
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
11 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
DBV Technologies Reports First Quarter 2023 Financial Results
4 May 23
8-K
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
19 Apr 23
EFFECT
Notice of effectiveness
18 Apr 23
8-K
Submission of Matters to a Vote of Security Holders
13 Apr 23
CORRESP
Correspondence with SEC
13 Apr 23
UPLOAD
Letter from SEC
13 Apr 23
S-3
Shelf registration
6 Apr 23
ARS
2022 FY
Annual report to shareholders
24 Mar 23
DEF 14A
Definitive proxy
24 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
PRE 14A
Preliminary proxy
8 Mar 23
8-K
DBV Technologies Announces First Patient
7 Mar 23
8-K
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
2 Mar 23
10-K
2022 FY
Annual report
2 Mar 23
8-K
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
23 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
DBV Technologies Reports Third Quarter Financial Results and Business Update
3 Nov 22
8-K
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
4 Oct 22
8-K
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
21 Sep 22
8-K
DBV expects to screen the first patient in Q4 2022 and anticipates topline results for the VITESSE study to read out in Q1 2025
7 Sep 22
Latest ownership filings
4
Daniel Tasse
11 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
BRAIDWELL LP
14 Feb 24
4
Adora Ndu
8 Feb 24
4
Pharis Mohideen
19 Dec 23
4
Virginie Boucinha
22 Nov 23
4
Daniel Tasse
22 Nov 23
4
Pharis Mohideen
22 Nov 23
3
Virginie Boucinha
7 Nov 23
4
TIMOTHY E MORRIS
28 Aug 23
4
Daniel Tasse
14 Aug 23
4
Pharis Mohideen
14 Aug 23
4
Sebastien Robitaille
14 Aug 23
4
DANIEL B SOLAND
3 Aug 23
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 23
SC 13G
BRAIDWELL LP
14 Feb 23
3
Daniele Guyot-Caparros
6 Oct 22
SC 13G
Venrock Healthcare Capital Partners II, L.P.
23 Jun 22
SC 13D/A
Bpifrance Participations SA
16 Jun 22
4
JULIAN BAKER
13 Jun 22
SC 13D/A
BAKER BROS. ADVISORS LP
13 Jun 22
SC 13G/A
Boxer Capital, LLC
14 Feb 22
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 22
4
Daniel Tasse
24 Nov 21
4
Pharis Mohideen
24 Nov 21
4
Sebastien Robitaille
24 Nov 21
4
DANIEL B SOLAND
11 Jun 21
4
Adora Ndu
11 Jun 21
4
TIMOTHY E MORRIS
11 Jun 21
4
Viviane Monges
11 Jun 21
4
ROSEN MICHEL DE
11 Jun 21
4
Madduri Ravin Rao
11 Jun 21
SC 13G/A
MORGAN STANLEY
10 Jun 21
3
Madduri Ravin Rao
1 Jun 21
3
Adora Ndu
1 Jun 21
3
TIMOTHY E MORRIS
2 Apr 21
SC 13G/A
Boxer Capital, LLC
16 Feb 21
SC 13G/A
PERCEPTIVE ADVISORS LLC
16 Feb 21
SC 13D/A
Bpifrance Participations SA
12 Feb 21
SC 13G/A
Flynn James E
12 Feb 21